Table 5.
Lack of functional interactions among A1, GABAB, and α2A receptors
| Frequency (%) | ncells, nexp | |
|---|---|---|
| A1R/GABABR | ||
| CPAa | 2.4 ± 2.1 | 20, 3 |
| → + baclofen | 1.8 ± 1.6n.s. | |
| Baclofen | 41.5 ± 7.6 | 18, 3 |
| → + CPA | 2.7 ± 0.2* | |
| A1R/α2AR | ||
| CPA | 8.9 ± 8.8 | 19, 3 |
| → + Guanfacine | 8.4 ± 3.3n.s. | |
| Guanfacine | 39.2 ± 8.3 | 17, 3 |
| → + CPA | 3.8 ± 1.9* | |
| α2AR/GABABR | ||
| Guanfacine | 51.2 ± 11.6 | 16, 3 |
| → + Baclofen | 42.4 ± 9.8n.s. | |
| Baclofen | 60.1 ± 5.4 | 18, 3 |
| → + Guanfacine | 41.6 ± 7.5n.s. | |
Data are expressed as a percentage of the frequency observed in baseline conditions or as the mean ± SEM. n.s., not significant. ANOVA, Bonferroni correction, for n cells from n experiments. Statistical significance indicated for comparisons between the two displayed conditions.
aConcentrations used: 30 nm CPA, 0.5 μm baclofen, and 10 μm guanfacine.
*p < 0.05.